An In-Depth Look at Merus N.V’s (MRUS) Stock Performance

14h ago, source: newsheater

Based on Merus N.V (MRUS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -11.57. The debt to equity ratio resting at 0 ...

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

11d ago, source: Yahoo Finance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the ...

Merus NV MRUS

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

16d ago, source: Yahoo Finance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

Merus N.V. (MRUS)

12d ago, source: Yahoo Finance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our ...

Merus reports progress on cancer therapy at AACR meeting

11d ago, source: Investing

UTRECHT, The Netherlands and CAMBRIDGE, Mass. - Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company, presented preclinical data at the American Association of Cancer Research (AACR) Annual ...

Merus N.V.: Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

11d ago, source:

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific ...

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

16d ago, source: ADVFN

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg ...

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

12d ago, source: ADVFN

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ...